Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab

  • Technology appraisal guidance
  • TA357
  • Published: 
  • Last updated: 
Download guidance (PDF)

1 Guidance

1.1 Pembrolizumab is recommended as an option for treating advanced (unresectable or metastatic) melanoma in adults only:

  • after the disease has progressed with ipilimumab and, for BRAF V600 mutation‑positive disease, a BRAF or MEK inhibitor and

  • when the company provides pembrolizumab in line with the commercial access agreement with NHS England.